Navigation Links
Decision Biomarkers Launches System for Faster, Easier Quantification of Protein Biomarkers

WALTHAM, Mass., Jan. 18 /PRNewswire/ -- Decision Biomarkers Inc., a leading developer of protein biomarker analysis systems for pharmaceutical research and development, announced the launch of the AVANTRA(TM) biomarker workstation along with its innovative MAX BIOCHIP(TM) 8-plex cytokine immunoassay. The system's ease-of-use enables users to generate data in real-time, accelerating decision making and improving project productivity.

The AVANTRA(TM) biomarker workstation is the first multiplexed immunoassay system that enables non-specialized technicians to perform complex protein biomarker analyses in both the lab and directly at clinical trial sites. Plasma and serum samples can be analyzed on site by virtually anyone in real time. The system eliminates the need to send samples out to a specialized lab.

One emerging application for DBI's technology is adaptive clinical trials where data is needed quickly for fast decision making. "Plasma and serum samples can now be analyzed on-site immediately after collection, lowering costs and streamlining the clinical-trials process" commented Roger Dowd, President and CEO of Decision Biomarkers. 'With the growing trend in adaptive clinical trials, rapidly acquiring data with the AVANTRA(TM) -- an hour after collection, versus several weeks or months from a core lab -- greatly accelerates decision making and the progress of clinical trials."

Researchers in biomarker validation, preclinical and translational medicine programs are interested as well. According to Peter Maimonis, VP Biological Research at Decision Biomarkers, "By fully automating the multiplexed protein assay, we specifically designed the AVANTRA(TM) system with individual investigators and researchers in mind. The scientists that we target want to spend their time on higher value activities rather than focusing on the minutia of running immunoassays."

The new MAX BIOCHIP(TM) immunoassay cartridges providing fully automated and multiplexed immunoassays complement the AVANTRA(TM) workstation. The 8-plex cytokine biochip introduced with the AVANTRA(TM) is positioned to support research in inflammation, autoimmune response, oncology, infectious disease and vaccines. Other immunoassay biochips are planned for introduction later this year including a 10-plex angiogenesis panel and multiplex cardiovascular panel. DBI is also developing biomarker panels with customized content defined by the Company's collaborators.

About Decision Biomarkers Inc.

Decision Biomarkers is a privately-held life science tools company that has developed the next-generation technology for protein biomarker analysis. DBI is driving the widespread adoption of protein biomarker analysis with the first automated, multiplex immunoassay system that can be used in real-time by virtually anyone, anywhere in drug development, clinical trials and diagnostics.

Copyright (C) 2008 Decision Biomarkers Inc. All rights reserved.

SOURCE Decision Biomarkers Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Wyeth Consumer Healthcare Supports U.S. Food and Drug Administration Decision for Over-the-Counter Cough and Cold Medications in Children under Two Years of Age
2. U.S. District Court Decision About Eisais Legal Action Over Aricept ODT(R) ANDA Filing
3. Decision Biomarkers Awarded U.S. Patent for Protein Array Surface Chemistry
4. Scientists Using Social Media to Inform Lab Purchasing Decisions
5. NPS Pharmaceuticals to Report Third Quarter 2007 Financial Results and Nycomed Decision on GATTEX(TM) Partnership on November 1, 2007
6. Genta Completes Appeal of FDA Decision for Genasense(R) in CLL
7. New Data Reveal Ethnicity May Play Role in Weight Loss Decisions
8. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
9. Former Banc of America Securities Analyst David Maris Comments on Decision by Biovail to Drop Its Claims Against Him; Denies That He is Cooperating With Biovail
10. Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
11. Consumer Advocates Praise Interstate Stem Cell Open Meeting Decision
Post Your Comments:
(Date:10/11/2017)... , ... October 11, 2017 , ... Disappearing forests and ... lives of over 5.5 million people each year. Especially those living in larger cities ... Treepex - based in one of the most pollution-affected countries globally - decided to ...
(Date:10/10/2017)... Los Angeles, CA (PRWEB) , ... ... ... Pharmaceuticals, Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) ... all uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed ...
(Date:10/10/2017)... 10, 2017 SomaGenics announced the receipt of ... develop RealSeq®-SC (Single Cell), expected to be the first ... (including microRNAs) from single cells using NGS methods. The ... to accelerate development of approaches to analyze the heterogeneity ... "New techniques for measuring levels of mRNAs in individual ...
(Date:10/9/2017)... ... October 09, 2017 , ... The award-winning American Farmer television series ... 2018. American Farmer airs Tuesdays at 8:30aET on RFD-TV. , With global population ... challenge of how to continue to feed a growing nation. At the same time, ...
Breaking Biology Technology:
(Date:3/30/2017)... -- The research team of The Hong Kong Polytechnic ... by adopting ground breaking 3D fingerprint minutiae recovery and matching technology, ... accuracy for use in identification, crime investigation, immigration control, security of ... ... A research team led by Dr ...
(Date:3/29/2017)... the health IT company that operates the largest health ... today announced a Series B investment from BlueCross BlueShield ... investment and acquisition accelerates higi,s strategy to create the ... activities through the collection and workflow integration of ambient ... secures data today on behalf of over 36 million ...
(Date:3/27/2017)... ROCKVILLE CENTRE, N.Y. , March 27, 2017 ... by Healthcare Information and Management Systems Society (HIMSS) ... Analytics Outpatient EMR Adoption Model sm . In ... top 12% of U.S. hospitals using an electronic ... recognized CHS for its high level of EMR ...
Breaking Biology News(10 mins):